Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeoGenomicsNEO +15.90%70 EV-to-EBITDA is 169.37 as of Jul. 29, 2026, which is 478% above its 10-year median of 29.32. GuruFocus rates NEO with a GF Score™ of 70/100 and a GF Value™ of $16.71 (Fairly Valued). The stock has 3 warning signs investors should review. Among 118 Medical Diagnostics & Research companies, NeoGenomics ranks worse than 847456.78% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NeoGenomics's enterprise value is $2,284.6 Mil.
NeoGenomics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $13.5 Mil. Therefore, NeoGenomics's EV-to-EBITDA for today is 169.37.
The historical rank and industry rank for NeoGenomics's EV-to-EBITDA or its related term are showing as below:
NEO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -16718.84 Med: 29.32 Max: 447.8
Current: 169.37
During the past 13 years, the highest EV-to-EBITDA of NeoGenomics was 447.80. The lowest was -16718.84. And the median was 29.32.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
NeoGenomics (NAS:NEO) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NeoGenomics's PE Ratio (TTM) for today is calculated as:
NeoGenomics's share price for today is $15.53.
NeoGenomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.400.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for NeoGenomics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, NeoGenomics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeoGenomics EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NeoGenomics's EV-to-EBITDA falls into.
NeoGenomics's current Enterprise Value is $2,284.6 Mil.
NeoGenomics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeoGenomics (NEO) has a EV-to-EBITDA of 169.37 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NeoGenomics. This is 478% above median its historical median of 29.32. According to the industry distribution chart, NeoGenomics ranks #999999 out of 118 companies in the Medical Diagnostics & Research industry.
Is NeoGenomics' EV-to-EBITDA too high?
NeoGenomics' current EV-to-EBITDA of 169.37 is 478% above median its 10-year median of 29.32. The Medical Diagnostics & Research industry median EV-to-EBITDA is 15.53. NeoGenomics' value of 169.37 is 990.6% above this industry median. Based on the distribution chart, NeoGenomics ranks #999999 out of 118 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, NeoGenomics has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' EV-to-EBITDA compare to WGS and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, NeoGenomics ranks #999999 out of 118 companies for EV-to-EBITDA. This places NeoGenomics in the lower half of its industry. The industry median EV-to-EBITDA is 15.53. NeoGenomics' value of 169.37 is 990.6% above this benchmark. While the company's 10-year median is 29.32 vs. the industry median of 15.53, NeoGenomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.53, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeoGenomics's current EV-to-EBITDA of 169.37 is 990.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NeoGenomics. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeoGenomics's current EV-to-EBITDA is 169.37, which is 478% above median its own 10-year median of 29.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
Based on GuruFocus' analysis, NeoGenomics (NEO) is currently considered Fairly Valued. The stock's GF Value™ is $16.71, compared to a current price of $15.53 — trading 7.1% below its estimated fair value. The current EV-to-EBITDA is 169.37, which is 478% above median its 10-year median of 29.32 and 990.6% above the Medical Diagnostics & Research industry median of 15.53. NeoGenomics' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For NeoGenomics (NEO), the current EV-to-EBITDA is 169.37 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeoGenomics (NEO) Overvalued in 2026?
Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued.
The current stock price of $15.53 is trading 7.1% below its estimated GF Value™ of $16.71.
GuruFocus considers NeoGenomics to be Fairly Valued.
Key valuation signals for NEO:
EV-to-EBITDA: 169.37 (478% above median its 10-year median of 29.32)
GF Value™: $16.71 vs. price of $15.53 (7.1% below fair value)
Industry Position: 990.6% above the Medical Diagnostics & Research median (#999999 of 118)
No single metric tells the full story. See the NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
70GF Score
Get the complete analysis for NEO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEO has been successfully added to your 
